April issue of PharmaTimes Magazine is out now
Last month’s SmartDeals
Off-label under debate
You let us know your thoughts
News from the technology and marketing world
Changes to the 2015 ABPI Code
The new provisions of the 2015 ABPI Code of Practice will become fully effective from 1 May 2015. CompliMed takes us through the key amendments
Make an MSL stand out in healthcare systems
Honey, I shrunk the drugs
Nanomedicine might be on the small side but it promises to be big business
The NHS: reform or ruin?
Is it better to stick with the reforms or look to change the health service all over again?
UK General Election
7 May – who will you vote for? Undecided? Use our UK General Election guide to healthcare and life sciences
Follow the leader
Do copycat biologics have what it takes to fulfil their money-making and cost-cutting promise? Sales Awards
Put your skills to the test
We talk to last year’s winners on what they got out of the PharmaTimes Sales Awards competition
PPRS versus the statutory scheme
Which is the better option?
Simon White is head of learning and development at Janssen
“Don’t talk about us; talk with us”
Jan Geissler tells us how CML changed his life
Click here to see the latest PharmaTimes Magazine
To subscribe go to www.pharmatimes.com/subscribe; digital available from:
Outcomes: a gamechanger for pharma
Patient-recorded outcome measures are likely to become a key part of how healthcare is provided, funded and managed. But is industry ready?
Healthcare Writer Lynne Taylor
The British government’s determination to place health outcomes at the heart of NHS decision-making presents UK-based drugmakers with a unique and potentially huge advantage over their global competitors.
Working in collaboration with the NHS to identify a product’s true value – in other words its value to the patient – has the potential to boost levels of medicines uptake and could also lead to products arriving earlier to market, both in the UK and overseas, a PharmaTimes business meeting was told recently. Leading these potentially game-changing opportunities is the NHS patient-recorded outcome measures programme, which began in 2009.
Innovative drugmakers have included PROMs in their clinical trials for many years, and the data have also long been used in observational studies and population health surveys. “We have decades of experience using these instruments and pharma is way ahead of the game. The fact they are now being measured in healthcare systems changes everything,” Professor Nancy Devlin, research director at the Office of Health Economics told the meeting. Indeed, PROMs are likely to become a key part of how all healthcare is provided, funded and managed, The King’s Fund healthcare policy think-tank has forecast.
So what exactly are PROMs and why should this matter to pharma? You can find out by reading the full article online here
See what's coming up in the March issue [PDF]
Visions 2014 supplement
Creating a balance between
reimbursement and innovation
How to plan early
What more does pharma need to do?
We asked you what the big developments in 2014 will be?
Change is key to opportunity
What to adapt for
Future-proofing the sales team
An example of a new R&D model
Visions in a nutshell
The complete Visions 2014 supplement PDF is available to download
Subscription is free to qualifying UK subscribers
To read articles in full and features in the magazine, why not subscribe
Average circulation Jan - Dec 2013: 23,178